Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWRBiotechnology
+$4.49 today
- Market cap
- $6.09B
- Beta
- 1.27
- P/E (TTM)
- -38.4
- EPS (TTM)
- -$2.11
Volume 2.42M
Average 1.82M
ARWR Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR
Depreciation & Amortization · Q4 FY2026 · quarter ended Sep 2026
Depreciation & amortization grows in line with its trailing trend
Q4 FY2026 depreciation & amortization of $7.21M rose 12.8% year over year, ahead of the +11.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 8.2% from the prior quarter. Over 3 fiscal years it compounded at +28.7% a year.
Context
- Depreciation & amortization amounted to 5.9% of revenue in FY2026, up 3.0 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +12.8% holds above the trailing-twelve-month pace of +11.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2026
- 26.62M USD
- Year-over-year change
- +11.3%
- 4-year CAGR
- +26.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | 26.62M | +11.3% |
| FY2025 | 2025-09-30 | 23.93M | +28.7% |
| FY2024 | 2024-09-30 | 18.6M | +48.8% |
| FY2023 | 2023-09-30 | 12.49M | +19.9% |
| FY2022 | 2022-09-30 | 10.42M | — |
Depreciation & Amortization vs competitors
How ARWR compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +11.3% is the highest of 6, against a peer median of -0.9%.
- Depreciation & amortization amounts to 5.9% of revenue for ARWR, versus a peer median of 9.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $54.76M USD | -3.1% | +7.8% | 1.1% | |
| LTM Sep 2026 | $26.62M USD | +11.3% | +28.7% | 5.9% | |
| LTM Sep 2026 | $21.89M USD | +6.2% | +0.9% | 2.3% | |
| LTM Mar 2026 | $8.99M USD | +4.0% | -4.3% | 12.5% | |
| LTM Mar 2026 | $2.88M USD | -16.2% | +25.6% | 6.4% | |
| LTM Mar 2026 | €2.72M EUR | -0.9% | +1.0% | 20.3% | |
| LTM Mar 2026 | $577.79K USD | — | +4.5% | 62.7% | |
| Peer median (excluding ARWR) | — | -0.9% | +2.8% | 9.4% | |
Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Revenue | 243.23M | 240.74M | 3.55M | 829.45M | 450.82M |
| Cost of Revenue | 10.42M | 12.49M | 18.6M | 0 | 1.8M |
| Gross Profit | 232.81M | 228.24M | (15.04M) | 829.45M | 449.02M |
| Gross Margin | 95.7% | 94.8% | -423.7% | 100.0% | 99.6% |
| Research & Development | 288.5M | 342.31M | 489.22M | 607.16M | 739.14M |
| Selling, General & Admin | 124.43M | 90.93M | 96.82M | 121.92M | 202.05M |
| Operating Expenses | 411.32M | 433.24M | 586.04M | 731.1M | 1.16B |
| Depreciation & Amortization | 10.42M | 12.49M | 18.6M | 23.93M | 26.62M |
| EBITDA | (162.29M) | (175.67M) | (561.51M) | 164.82M | (603.59M) |
| EBITDA Margin | -66.7% | -73.0% | -15812.8% | 19.9% | -133.9% |
| Operating Income | (178.51M) | (205M) | (601.08M) | 98.35M | (707.17M) |
| Operating Margin | -73.4% | -85.2% | -16927.1% | 11.9% | -156.9% |
| Interest Income | 5.03M | 15.3M | 22.72M | 37.29M | 57.86M |
| Interest Expense | 0 | 18.33M | 32.35M | 89.36M | 93.71M |
| Other Income / Expenses | 5.8M | (1.49M) | (11.38M) | (46.81M) | (16.74M) |
| Income Before Tax | (172.71M) | (206.49M) | (612.46M) | 51.53M | (723.92M) |
| Pre-Tax Margin | -71.0% | -85.8% | -17247.5% | 6.2% | -160.6% |
| Income Tax Expense | 3.79M | 2.78M | (2.77M) | 21.42M | (6.78M) |
| Net Income | (176.06M) | (205.28M) | (599.49M) | (1.63M) | (724.21M) |
| Net Margin | -72.4% | -85.3% | -16882.4% | -0.2% | -160.6% |
| EPS (Basic) | (1.67) | (1.92) | (5.00) | (0.01) | (5.11) |
| EPS (Diluted) | (1.67) | (1.92) | (5.00) | (0.01) | (5.11) |
| Weighted Avg Shares | 105.43M | 106.75M | 119.78M | 133.76M | 141.63M |
| Weighted Avg Shares (Diluted) | 105.43M | 106.75M | 119.78M | 133.76M | 141.63M |
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
Intrinsic Alpha fair value
Locked
Current Price
$43.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.